The Medical Devices Special Access Program in Canada: A Scoping Study

How to calculate the life cycle of high-risk medical devices for patient safety

In this study, we analyzed Korean and foreign systems, focusing on high-risk medical devices that urgently need to be managed, and we present an life cycle calculation method for determining replacement time. A literature review was conducted to confirm the regulations of the medical device management system and life cycle by country, and a case analysis was performed to verify the replacement evaluation criteria of actual medical institutions. In addition, durability data from the Public Procurement Service, American Hospital Association, and Samsung Medical Center were used to calculate the life cycle of high-risk medical devices. The analysis showed that in the case of Korean and foreign medical device regulatory agencies, there were no specific life cycle regulations for high-risk medical devices. In addition, the important items in the medical device replacement evaluation were found to be the year of introduction, repair cost, component discontinuation, and several failures. On calculating the life cycle of high-risk medical devices revealed that the replacement time is 13 years for anesthesia machines, 14 years for defibrillators, 16 years for heart-lung machines, and 13 years for ventilators. To introduce a uniform medical device replacement standard and life cycle calculation method, the government will need to reorganize the medical device replacement laws and systems. In addition, in the case of medical institutions, it is necessary to secure patient safety by using expert groups to prepare specific life cycle standards that consider the characteristics of medical devices.

Effect of medical innovation policies on the prevention and control of the COVID-19 and the impact of the "Belt and Road" economy

With the spread of the COVID-19, it is urgent for everyone to protect themselves. The introduction of the medical innovation policy has also brought certain effects to the prevention and control of the COVID-19. The specific effect will be reflected in the following research. This paper firstly analyzed research results related to medical innovation policy, COVID-19 prevention and control, and the "One Belt, One Road" economy, finding out the content that fits this research, and innovates the research work on this basis. Then, this paper provided a detailed explanation of medical innovation policies, the prevention and control of the COVID-19, and the "One Belt, One Road" economy. Among them, this paper focuses on the "One Belt and One Road," uses the α-convergence model to analyze the economic changes of the "One Belt and One Road," and conducts experimental tests in the medical field. The results have shown that from 2017 to 2019, the average hospitalization expenses paid by the pooled funds were 4986.19, 4997.34, and 4888.60 yuan, respectively.